+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pancreatitis - Pipeline Review, H1 2020

  • ID: 5017471
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 101 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Angion Biomedica Corp
  • BioNTech SE
  • Cypralis Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mallinckrodt Plc
  • MORE
Pancreatitis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H1 2020, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.

Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 1, 14, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Angion Biomedica Corp
  • BioNTech SE
  • Cypralis Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mallinckrodt Plc
  • MORE
  • Introduction
  • Pancreatitis - Overview
  • Pancreatitis - Therapeutics Development
  • Pancreatitis - Therapeutics Assessment
  • Pancreatitis - Companies Involved in Therapeutics Development
  • Pancreatitis - Drug Profiles
  • Pancreatitis - Dormant Projects
  • Pancreatitis - Discontinued Products
  • Pancreatitis - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Pancreatitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pancreatitis - Pipeline by Angion Biomedica Corp, H1 2020
  • Pancreatitis - Pipeline by Bessor Pharma LLC, H1 2020
  • Pancreatitis - Pipeline by Bharat Serums And Vaccines Ltd, H1 2020
  • Pancreatitis - Pipeline by BioNTech SE, H1 2020
  • Pancreatitis - Pipeline by CalciMedica Inc, H1 2020
  • Pancreatitis - Pipeline by Centeer BioTherapeutics Ltd Co, H1 2020
  • Pancreatitis - Pipeline by Cypralis Ltd, H1 2020
  • Pancreatitis - Pipeline by D&D Pharmatech Co Ltd, H1 2020
  • Pancreatitis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
  • Pancreatitis - Pipeline by General Regeneratives Shanghai Ltd, H1 2020
  • Pancreatitis - Pipeline by Generon (Shanghai) Corp Ltd, H1 2020
  • Pancreatitis - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Pancreatitis - Pipeline by GNT Pharma Co Ltd, H1 2020
  • Pancreatitis - Pipeline by Johnson & Johnson, H1 2020
  • Pancreatitis - Dormant Projects, H1 2020
  • Pancreatitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Pancreatitis - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Pancreatitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Angion Biomedica Corp
  • Bessor Pharma LLC
  • Bharat Serums And Vaccines Ltd
  • BioNTech SE
  • CalciMedica Inc
  • Centeer BioTherapeutics Ltd Co
  • Cypralis Ltd
  • D&D Pharmatech Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • General Regeneratives Shanghai Ltd
  • Generon (Shanghai) Corp Ltd
  • GlaxoSmithKline Plc
  • GNT Pharma Co Ltd
  • Johnson & Johnson
  • LipimetiX Development Inc
  • Mallinckrodt Plc
  • Novartis AG
  • PNB Vesper Life Science Pvt Ltd
  • SCM lifescience Co Ltd
  • Shenzhen HighTide Biopharmaceutical Ltd
  • SN BioScience
  • Sun BioPharma Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll